Smart Immune
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Acute Leukemia After T Cell Depleted Allo-HSCT
What's the purpose of the trial?
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with relapsed/refractory acute leukemia.
Accepting patients
For Healthcare Professionals Only
This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.
Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Allogeneic Stem Cell Transplant is a type of stem cell transplant that utilizes a donor's pre-collected stem cells to rescue the bone marrow from the toxic effects of very high dose chemotherapy.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.